Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation
| Autor: | Maki Oiwa-Monna, Hiroto Ishii, Shinji Mochizuki, Satoshi Takahashi, Tomomi Takei, Yasuhiro Ebihara, Takaaki Konuma, Jun Ooi, Seiko Kato, Arinobu Tojo |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Transplantation Conditioning Allogeneic transplantation Adolescent Platelet Engraftment Graft vs Host Disease Young Adult 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Transplantation Homologous Cumulative incidence Retrospective Studies Transplantation Chimera business.industry Hematopoietic Stem Cell Transplantation Myeloid leukemia Hematology Middle Aged medicine.disease Transplantation Treatment Outcome Hematologic Neoplasms 030220 oncology & carcinogenesis Cord blood Retreatment Immunology Female Stem cell Unrelated Donors business 030215 immunology Chronic myelogenous leukemia |
| Zdroj: | Leukemia & Lymphoma. 57:103-109 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.3109/10428194.2015.1045900 |
| Popis: | The efficacy of second allogeneic stem cell transplantation (SCT2) using cord blood (CB) for patients with relapsed hematological malignancies after initial allogeneic stem cell transplantation (SCT1) is unknown. We analyzed the results of SCT2 using single-unit unrelated CB in 34 adult patients with relapsed hematological malignancies after SCT1 in our institution. The patients had acute myeloid leukemia (n = 23), acute lymphoblastic leukemia (n = 7), chronic myelogenous leukemia (n = 2), and myelodysplastic syndrome (n = 2). The cumulative incidence of neutrophil and platelet engraftment was 81.6% at 30 days and 68.5% at 100 days, respectively. With a median follow-up of 40 months, the probability of overall survival at 3 years was 29.0%. The cumulative incidence of relapse and transplant-related mortality at 3 years were 60.7% and 27.2%, respectively. The use of CB could offer the opportunity to receive SCT2 for patients who experienced disease relapse after SCT1 without HLA-identical related or unrelated donors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|